Stock News

Companhia Siderúrgica Nacional (SID) Reaches $2.49 After 6.00% Down Move; Cortina Asset Management Cut Ligand Pharmaceuticals (LGND) Stake By $1.25 Million

Companhia Siderúrgica Nacional (NYSE:SID) Logo

Cortina Asset Management Llc decreased Ligand Pharmaceuticals (LGND) stake by 20.42% reported in 2017Q4 SEC filing. Cortina Asset Management Llc sold 9,218 shares as Ligand Pharmaceuticals (LGND)’s stock rose 20.51%. The Cortina Asset Management Llc holds 35,916 shares with $4.92M value, down from 45,134 last quarter. Ligand Pharmaceuticals now has $3.56B valuation. The stock increased 1.25% or $2.07 during the last trading session, reaching $167.74. About 63,857 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 53.11% since April 16, 2017 and is uptrending. It has outperformed by 41.56% the S&P500.

The stock of Companhia Siderúrgica Nacional (NYSE:SID) is a huge mover today! The stock decreased 1.58% or $0.04 during the last trading session, reaching $2.49. About 1.29 million shares traded. Companhia Siderúrgica Nacional (NYSE:SID) has declined 22.43% since April 16, 2017 and is downtrending. It has underperformed by 33.98% the S&P500.The move comes after 9 months negative chart setup for the $3.56 billion company. It was reported on Apr, 16 by We have $2.34 PT which if reached, will make NYSE:SID worth $213.60 million less.

Companhia Siderúrgica Nacional operates as an integrated steel producer in Brazil. The company has market cap of $3.56 billion. It operates through Steel, Mining, Logistics, Cement, and Energy divisions. It has a 1245 P/E ratio. It offers steel products, such as coated sheets, galvanized steel, pre-painted steel, metal sheets, and flat and long steel products for automotive, civil construction, packaging, appliances, OEM, and distribution markets.

Cortina Asset Management Llc increased Supernus Pharmaceuticals Inc (NASDAQ:SUPN) stake by 72,721 shares to 166,321 valued at $6.63M in 2017Q4. It also upped Silicon Motion Technol (NASDAQ:SIMO) stake by 62,900 shares and now owns 151,050 shares. Axon Enterprise Inc was raised too.

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on May, 8. They expect $0.48 EPS, up 23.08% or $0.09 from last year’s $0.39 per share. LGND’s profit will be $10.18 million for 87.36 P/E if the $0.48 EPS becomes a reality. After $1.03 actual EPS reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -53.40% negative EPS growth.

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals had 29 analyst reports since September 3, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, October 11 by Roth Capital. Roth Capital maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) rating on Monday, February 26. Roth Capital has “Buy” rating and $171.0 target. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Buy” rating given on Wednesday, September 30 by Roth Capital. Craig Hallum maintained it with “Buy” rating and $190.0 target in Thursday, February 22 report. The firm has “Buy” rating given on Friday, March 11 by Roth Capital. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Buy” rating given on Thursday, September 3 by Roth Capital. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Buy” rating given on Friday, December 18 by TH Capital. Stephens maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Thursday, February 22 with “Buy” rating. Roth Capital maintained the shares of LGND in report on Monday, September 21 with “Buy” rating. As per Thursday, November 9, the company rating was maintained by H.C. Wainwright.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *